Paper Details

  1. Home
  2. Paper Details

Reported sildenafil side effects in pediatric pulmonary hypertension patients.

Author: FeinsteinJeffrey A, McCarthyElisa K, OgawaMichelle T, SiehrStephanie L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

The incidence of vascular, gastrointestinal, and neurologic side effects in pediatric patients on sildenafil therapy for pulmonary arterial hypertension (PAH) was 30%. Side effects were more common in patients on combination therapy with an endothelin receptor antagonist (ERA) and/or prostacyclin than in patients on sildenafil monotherapy.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Sildenafil, a phosphodiestase type 5 inhibitor, was approved in 2005 for the treatment of pulmonary arterial hypertension (PAH) in adults and is commonly used off-label for pediatric patients. Little is known, however, about sildenafil's side effects in this population. METHODS: Single ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353247/

データ提供：米国国立医学図書館（NLM）

Sildenafil: Exploring the Side Effect Landscape in Pediatric Pulmonary Hypertension

This study investigates the safety profile of sildenafil, a phosphodiesterase type 5 inhibitor, in pediatric patients with pulmonary arterial hypertension (PAH). The researchers conducted a longitudinal survey-based study to assess the frequency of various side effects associated with sildenafil therapy. This research provides valuable insights into the potential risks and benefits of sildenafil use in this patient population.

Navigating the Challenges of Pediatric PAH Treatment

This study highlights the importance of understanding the unique needs of pediatric patients with PAH and the potential side effects of medications used to treat this condition. The researchers' findings underscore the importance of careful monitoring and assessment of side effects in this vulnerable patient population. This research can guide healthcare providers in making informed decisions regarding sildenafil therapy for pediatric PAH patients.

The Importance of Personalized Care and Ongoing Monitoring

This study emphasizes the need for personalized care and ongoing monitoring in pediatric PAH treatment. The researchers' findings suggest that the frequency of side effects may vary depending on the specific treatment regimen and individual patient factors. This underscores the importance of a collaborative approach between healthcare providers and families to ensure the safe and effective management of PAH in children.

Dr.Camel's Conclusion

This research is like a guidebook for navigating the complex terrain of pediatric pulmonary hypertension treatment. By carefully considering the potential risks and benefits of medications like sildenafil, healthcare providers can ensure the best possible outcomes for their young patients. This study reminds us that the journey of healthcare is often a collaborative one, requiring careful monitoring and a focus on the unique needs of each individual patient.

Date :
  1. Date Completed 2015-03-25
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

25806361

DOI: Digital Object Identifier

PMC4353247

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.